---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-033551"
form_type: "8-K"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2023-10-03T23:59:59+00:00"
generated_at: "2026-06-10T05:37:19.422688+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zymergen subsidiary files Chapter 11; Ginkgo to acquire IP assets as stalking horse bidder

## Summary
- Zymergen Inc., a wholly-owned subsidiary of Ginkgo, filed voluntary Chapter 11 petitions on October 3, 2023 in Delaware.
- Neither Ginkgo nor its other subsidiaries filed for bankruptcy; Ginkgo remains well capitalized with $1.1B cash as of Q2 2023.
- Ginkgo entered an asset purchase agreement as stalking horse bidder to acquire exclusive rights to substantially all Zymergen IP assets.
- Bid includes $5M cash and assumption of up to $77M in future liabilities (lease, employee compensation and severance).
- Existing non-exclusive license for Zymergen's databases, automation, and software remains unaffected by the bankruptcy process.

## SEC filing metadata
- accession: 0001628280-23-033551
- form_type: 8-K
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2023-10-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000162828023033551/0001628280-23-033551-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000162828023033551/dna-20231003.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-033551
- JSON: https://secwatch.observer/filing/0001628280-23-033551.json
- Plain text: https://secwatch.observer/filing/0001628280-23-033551.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.